Suicides and parasuicides in a high-risk group on and off lithium long-term medication
Department of Psychiatry, Free University of Berlin, FRG.Journal of Affective Disorders (Impact Factor: 3.38). 09/1992; 25(4):261-9. DOI: 10.1016/0165-0327(92)90084-J
68 patients with affective disorders, and receiving lithium prophylaxis in a specialized lithium clinic were followed up for 8 years on average. Patients were selected for this study according to 2 criteria: They had been given lithium for at least 12 months, and they had attempted suicide at least once before onset of lithium prophylaxis. Outcome was analysed in terms of suicidal and parasuicidal behaviour. 55 patients took their lithium regularly, 13 discontinued or dropped the medication. One third of those patients having discontinued the medication died from suicide. Only one suicide occurred in patients with regular lithium intake and proven compliance during the last check before death. An impressive drop of parasuicides was observed in responders as well as in apparent non-responders. In total, 11 of 13 patients showed suicidal or parasuicidal behaviour 2 weeks-44 months after lithium discontinuation, which in about half of these cases took place on advice or with consent of the treating psychiatrist. It is concluded that lithium may have specific anti-suicidal properties, possibly related to its anti-aggressive effect, and that patients apparently not responding satisfactorily in terms of reduced number of episodes may still be protected against suicide or parasuicide.
- "Early detection and adequate treatment of a primary psychiatric disorder is of paramount importance. In psychiatrically ill subjects, lithium,[152–154] clozapine.[155–157] olanzapine, antidepressants, and behavioral interventions such as dialectical behavior therapy, DBT have been shown to have antisuicidal effects. "
Article: Suicide: An Indian perspective[Show abstract] [Hide abstract]
ABSTRACT: Suicide is the third leading cause of death among young adults worldwide. There is a growing recognition that prevention strategies need to be tailored to the region-specific demographics of a country and to be implemented in a culturally-sensitive manner. This review explores the historical, epidemiological and demographic factors of suicide in India and examines the strategies aimed at the prevention of suicide. There has been an increase in the rates of suicide in India over the years, although trends of both increases and decline in suicide rates have been present. Distinct from global demographic risk factors, In India, marital status is not necessarily protective and the female: male ratio in the rate of suicide is higher. The motives and modes of suicide are also distinct from western countries. Preventive strategies implemented at a community level and identifying vulnerable individuals maybe more effective than global strategies.Indian Journal of Psychiatry 03/2012; 54(4):304-319. DOI:10.4103/0019-5545.104793
[Show abstract] [Hide abstract]
- "However, post-mortem brain donors with a history of BD are most often suicide completers. The literature provides extensive evidence for the anti-suicidal effects of Li prophylaxis through observational studies , , randomized controlled studies ,  and meta-analyses , . Thus, such a study would be logistically quite challenging. "
ABSTRACT: Bipolar disorder (BD) is a debilitating psychiatric condition with a prevalence of 1-2% in the general population that is characterized by severe episodic shifts in mood ranging from depressive to manic episodes. One of the most common treatments is lithium (Li), with successful response in 30-60% of patients. Synapsin II (SYN2) is a neuronal phosphoprotein that we have previously identified as a possible candidate gene for the etiology of BD and/or response to Li treatment in a genome-wide linkage study focusing on BD patients characterized for excellent response to Li prophylaxis. In the present study we investigated the role of this gene in BD, particularly as it pertains to Li treatment. We investigated the effect of lithium treatment on the expression of SYN2 in lymphoblastoid cell lines from patients characterized as excellent Li-responders, non-responders, as well as non-psychiatric controls. Finally, we sought to determine if Li has a cell-type-specific effect on gene expression in neuronal-derived cell lines. In both in vitro models, we found SYN2 to be modulated by the presence of Li. By focusing on Li-responsive BD we have identified a potential mechanism for Li response in some patients.PLoS ONE 02/2012; 7(2):e32680. DOI:10.1371/journal.pone.0032680 · 3.23 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Die Behandlung suizidaler Patienten gehört zu den anspruchvollsten Herausforderungen für alle Professionen im Gesundheitswesen. Aufgrund der enormen gesundheitspolitischen Bedeutung ist die Therapie suizidalen Verhaltens in den letzten Jahren mehr und mehr in den Mittelpunkt psychiatrischer Forschung gerückt und nimmt einen größeren Stellenwert in der Erarbeitung von Behandlungs- und Präventionsstrategien ein. Für Lithium als eine der ältesten in der Psychiatrie verwendeten psychotropen Substanzen wurde seit Anfang der 1990iger Jahre ein eigenständiger, im Vergleich zu anderen Psychopharmaka wahrscheinlich spezifischer antisuizidaler Effekt nachgewiesen. Trotz dieses Wissens und des heute ebenfalls in nationalen und internationalen Leitlinien dokumentierten Stellenwertes von Lithium in der Akut- und Erhaltungstherapie affektiver Störungen ist Lithium hinsichtlich seiner Verschreibungshäufigkeit im Vergleich zu anderen Psychopharmaka unterrepräsentiert. Der folgende Beitrag gibt eine chronologische Zusammenfassung aller wichtigen Studien, welche die antisuizidale Wirkung von Lithium untersucht haben, und diskutiert die daraus resultierenden therapeutischen Implikationen.Der Nervenarzt 03/2012; 84(3). DOI:10.1007/s00115-012-3542-5 · 0.79 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.